MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-11-2026
Bristol-Myers Squibb Company ROE Ratio 2011-2026 | BMY
Annual ROE Ratio Bristol-Myers Squibb Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 38.19 | -54.78 | 27.27 | 20.37 | 19.46 | -23.84 | 6.65 | 34.83 | 8.5 | 27.26 | 10.85 | 13.38 | 16.82 | 14.37 | 23.38 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 38.19 | -54.78 | 12.18 |
Quarterly ROE Ratio Bristol-Myers Squibb Company
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 38.58 | -41.17 | -48.64 | -49.23 | -51.99 | 25.16 | 23.42 | 20.99 | 13.01 | 17.16 | 12.36 | 15.22 | 12.39 | -14.12 | -13.32 | -16.41 | -23.84 | 0.63 | -1.7 | 1.3 | 6.66 | 16.98 | 27.91 | 27.79 | 35.07 | 6.97 | 0.62 | 5.76 | 8.58 | 33.93 | 34.16 | 33.57 | 27.55 | 20.64 | 18.16 | 10.04 | 10.97 | 12.44 | 12.34 | 15.5 | 13.49 | 18.2 | 17.91 | 19.2 | 16.91 | 18.91 | 9.13 | 10.32 | 14.39 | 12.94 | 24.23 | 25.15 | 23.25 | 6.07 | 5.65 | 6.18 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 38.58 | -51.99 | 9.42 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
Acer Therapeutics
ACER
|
156.54 | - | 2.71 % | $ 14 M |  USA |
 |
Acasti Pharma
ACST
|
-14.36 | - | 4.01 % | $ 150 M |  Canada |
 |
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M |  China |
 |
Adverum Biotechnologies
ADVM
|
-185.15 | - | - | $ 86.2 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
-48.89 | $ 4.16 | 6.02 % | $ 355 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Adagene
ADAG
|
-66.16 | $ 3.16 | 10.88 % | $ 178 M | China |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M |  France |
 |
Akouos
AKUS
|
-37.09 | - | 0.23 % | $ 488 M | USA |
 |
Aptorum Group Limited
APM
|
-20.19 | $ 0.75 | -11.96 % | $ 4.09 M | China |
 |
AlloVir
ALVR
|
-51.87 | - | 4.14 % | $ 49.1 M | USA |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-256.9 | - | -11.43 % | $ 502 K | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-36.22 | $ 3.47 | -1.12 % | $ 8.35 B |  Australia |
 |
Applied Molecular Transport
AMTI
|
-207.64 | - | - | $ 10.1 M | USA |
 |
ARCA biopharma
ABIO
|
-21.9 | - | 1052.0 % | $ 415 M | USA |
 |
Acorda Therapeutics
ACOR
|
160.08 | - | -24.86 % | $ 820 K | USA |
 |
Aptose Biosciences
APTO
|
559.76 | - | -45.71 % | $ 1.2 M | Canada |
 |
Akero Therapeutics
AKRO
|
-33.6 | - | - | $ 3.67 B | USA |
 |
Athira Pharma
ATHA
|
-216.19 | - | - | $ 269 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-40.17 | - | - | $ 1.01 B | USA |
 |
Albireo Pharma
ALBO
|
-19.38 | - | -0.23 % | $ 916 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
Allena Pharmaceuticals
ALNA
|
-257.91 | - | 3.16 % | $ 1.9 M | USA |
 |
Ascendis Pharma A/S
ASND
|
-43.41 | $ 217.7 | -0.18 % | $ 5 B |  Danmark |
 |
Aptinyx
APTX
|
-169.38 | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
-716.17 | - | -13.39 % | $ 1.45 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-91.56 | - | -6.81 % | $ 3.04 B | USA |
 |
Aridis Pharmaceuticals
ARDS
|
125.33 | - | 17.91 % | $ 11.1 M | USA |
 |
Biogen
BIIB
|
7.08 | $ 197.98 | 1.27 % | $ 29 B | USA |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M | Canada |
 |
Brickell Biotech
BBI
|
-57.34 | - | -5.38 % | $ 6.06 M | USA |
 |
AgeX Therapeutics
AGE
|
-270.67 | - | -10.17 % | $ 12.2 K | USA |
 |
Athersys
ATHX
|
-531.22 | - | 3.77 % | $ 22.4 M | USA |
 |
BioNTech SE
BNTX
|
1.11 | $ 107.93 | 2.05 % | $ 27.2 B | Germany |
 |
Avenue Therapeutics
ATXI
|
-418.16 | - | -52.27 % | $ 4.45 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-19.35 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Autolus Therapeutics plc
AUTL
|
-51.64 | $ 1.42 | 2.9 % | $ 362 M | Britain |
 |
Burford Capital Limited
BUR
|
10.1 | $ 9.4 | 1.02 % | $ 1.51 B | Britain |
 |
Amneal Pharmaceuticals
AMRX
|
67.61 | $ 14.93 | 2.05 % | $ 4.61 B | USA |
 |
AIkido Pharma
AIKI
|
-36.89 | - | 1.93 % | $ 17.4 M | USA |
 |
AVROBIO
AVRO
|
12.83 | - | 1083.1 % | $ 745 M | USA |
 |
CureVac N.V.
CVAC
|
-59.8 | - | - | $ 867 M | Germany |
 |
Alpine Immune Sciences
ALPN
|
-32.19 | - | - | $ 2.17 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3458.87 | - | - | $ 7.46 M |  Israel |